Science Current Events | Science News | Brightsurf.com
 

Multiple myeloma patient study shows promise for natural killer cells

December 08, 2015

A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments.

Multiple myeloma is a cancer that forms from white blood cells that are found in the bone marrow and are normally vital to a healthy immune system. Natural killer (NK) cells are white blood cells that roam through the blood stream, attacking infections and potentially cancer-causing cells. The technology to grow NK cells from umbilical cord blood was developed by Nina Shah, M.D., assistant professor and Elizabeth J. Shpall, M.D., professor in the department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center.

Results from the clinical study, led by Shah and Shpall, were presented today at the 57th Annual Meeting of the American Society of Hematology (ASH) annual conference in Orlando, Fla.

"Multiple myeloma is an incurable disease thought to be characterized by immune dysregulation and exhaustion, whereby proliferation of malignant plasma cells is not checked by the immune system," said Shah. "Long-term remissions in some patients after stem cell transplants from donors have been observed, but treatment-related toxicity limits the widespread use of this therapy."

Shah and Shpall's team enrolled symptomatic patients who qualified as candidates for high-dose chemotherapy drugs like melphalan, and transplantation of the patient's own stem cells.

"Successful natural killer cell expansion to target dose was achieved in all the patients," said Shah. "The cell therapy infusion resulted in no toxicity and no occurrences of graft-versus-host disease."

Graft-versus-host disease is a condition in which the patient's immune system is attacked by the donor stem cells. The disease can occur in patients who have received donor stem cells or immune.

Twelve patients were enrolled in the study and were divided into four separate groups, with each receiving different dose levels of cord blood-derived natural killer cells. Ten of the 12 patients demonstrated high-risk disease or relapse in disease prior to study participation.

###

MD Anderson team participants included Jessica McCarty, Eric Yvon, Ph.D., Hila Shaim, M.D., Muharrem Muftuoglu, Enli Liu, Catherine Sobieski, Simrit Parmar, M.D., Chitra Hosing, M.D., Sairah Ahmen, M.D., Yago Nieto, M.D., Ph.D., Qaiser Bashir, M.D., Krina Patel, Ian McNiece, Ph.D., Muzaffar Qazilbash, M.D. and Richard Champlin, M.D., all of the Department of Stem Cell Transplantation and Cellular Therapy; Li Li, Department of Experimental Radiation Oncology; Indreshpal Kaur, Department of Cancer Medicine; Robert Orlowski, M.D., Ph.D., Department of Lymphoma/Myeloma; Laurence Cooper, M.D, formerly of the Department of Pediatrics; Kai Cao, M.D., Department of Laboratory Medicine; and Dean Lee, M.D., Ph.D., Department of Pediatrics.

The study was funded by Celgene, Summit, N.J. and the High-Risk Multiple Myeloma Moon Shot program at MD Anderson.

University of Texas M. D. Anderson Cancer Center


Related Multiple Myeloma Current Events and Multiple Myeloma News Articles


Carnegie Mellon develops bio-mimicry method for preparing and labeling stem cells
Researchers led by Carnegie Mellon University Professor of Biological Sciences Chien Ho have developed a new method for preparing mesenchymal stem cells (MSCs) that not only leads to the production of more native stem cells, but also labels them with a FDA approved iron-oxide nanoparticle (Ferumoxytol).

Demand for radiotherapy will rise substantially over next 10 years
The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published in Radiotherapy and Oncology.

Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma
An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists.

Combination therapy may be better than radiotherapy alone to treat aggressive brain cancer
Radiotherapy effectively damages brain tumors but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend themselves.

Cancer treatment: Therapeutic approach gives hope for the treatment of multiple myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.

A new class of drug slows growth of castration-resistant prostate cancer cells
A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina (MUSC) and others.

Three studies point to effectiveness of new therapies for multiple myeloma
In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana-Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment-resistant forms of the disease.

New vaccine strategy better protects high-risk cancer patients from flu
Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.

Targeting protein homeostasis holds potential to treat solid tumors and blood cancers
The success of proteasome inhibitors such as VELCADE® (bortezomib) and Kyprolis® (carfilzomib) for the treatment of multiple myeloma has shown that protein homeostasis, which is how cells maintain a balance of protein synthesis and degradation, is a valid pathway for developing drugs to treat cancer.

Personalized drug screening on horizon for multiple myeloma patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
More Multiple Myeloma Current Events and Multiple Myeloma News Articles

Multiple Myeloma

Multiple Myeloma
by NetCE


Multiple myeloma is the second most prevalent hematologic cancer after non-Hodgkin lymphoma. While great strides have been made to improve survival rates with this disease, and positive outcomes have been attained over the last ten years, multiple myeloma remains an incurable disease. The purpose of this course is to provide healthcare professionals in contact with multiple myeloma patients the information necessary to provide optimum care, treatment, and patient education. In addition, members of the public may use this course to enhance their personal knowledge of the subject matter presented.

Upon completion of this course, you should be able to:

1. Review the history of multiple myeloma.
2. Describe the pathophysiology and differentiation of multiple...

Multiple Myeloma Patient Handbook: 2017 Edition

Multiple Myeloma Patient Handbook: 2017 Edition
by International Myeloma Foundation


One of the most daunting aspects of being diagnosed with myeloma is learning about an unfamiliar disease that is quite complicated. The IMF’s Patient Handbook provides an overview of myeloma, with a focus on getting the correct diagnosis, the tests you really need, initial treatment options, and supportive care and how to get it.

Multiple Myeloma Study Guide; Concise Information That Every Med Student, Physician, NP, and PA Should Know

Multiple Myeloma Study Guide; Concise Information That Every Med Student, Physician, NP, and PA Should Know
by Chart-MD


Just the facts are included in this book. Written by a board certified medical oncologist, this is the perfect text if you are looking for a quick review of the information you need to know about multiple myeloma. We won’t waste your time with this rapid access information. The Multiple myeloma Study Guide has distilled the key details down to the concise facts that you will understand and remember.

The Multiple Myeloma Study Guide is an ideal resource for medical students and anyone who wants to understand more about Multiple myeloma.

Sample Text:

Fact: In the United States, the lifetime risk of getting multiple myeloma is 1 in 161 (0.62%).

Fact: Urinary monoclonal protein elevations in multiple myeloma are more likely to be...

The Myeloma Survival Guide: Essential Advice for Patients and Their Loved Ones

The Myeloma Survival Guide: Essential Advice for Patients and Their Loved Ones
by Jim Tamkin MD FACP FACE (Author), Dave Visel (Author)


The definitive guide to living a longer, fuller life with myeloma The Myeloma Survival Guide makes sense of the difficult questions myeloma patients face, dealing with every aspect of life after diagnosis, from creating a wellness team to navigating treatment options to building a financial safety net. Jim Tamkin, MD, who lived with myeloma for 11 years, and Dave Visel share the insights they've gained as a doctor, patient, and caregiver, including: Everything you need to know about drugs and treatments, including stem cell transplants How to deal with the pain and side effects of chemotherapy, radiation, and surgery Insurance and tax benefits to save money and get you the care you deserve Take-charge tools you can use today to feel better tomorrow...

Multiple Myeloma: The Plain English Handbook for Patients and Care Givers

Multiple Myeloma: The Plain English Handbook for Patients and Care Givers
by Robert J. Heller (Author)


A comprehensive handbook and guide in easy to understand terms dealing with Multiple Myeloma; the disease, treatments, medications, lifestyle changes, and resources. Written by a non-medical author and based upon personal experiences. Updated annually.

HOPE: Journey with Multiple Myeloma

HOPE: Journey with Multiple Myeloma
by George Gadren Jr (Author)


Many people desire to write a book. I guess that piece for us is an attempt to make one immortal. Like so many other books, excluding the great ones, my attempt will end up on a dusty shelf with the pages untouched and that is just fine in my book, no pun intended. Our true living on beyond our short visit here on mortal earth does not live in a book, trophy or award but lives in what values we instill in our children. One word we may have shared with them may have made a difference. Those words I pray then echo into following generations. My desire here is to write a memoir touching on my life spent with cancer. At times my words may take form of a commentary. I have never been captive to the rules of formal writing and if it were not for word processing advanced editing tools my memoir...

Living with Multiple Myeloma

Living with Multiple Myeloma
by Pat Killingsworth (Author)


Best selling multiple myeloma patient memoir. First of three editions. Each edition has been carefully updated and expanded.

100 Questions  &  Answers About Myeloma (100 Questions and Answers)

100 Questions & Answers About Myeloma (100 Questions and Answers)
by Asad Bashey (Author), Rafat Abonour (Author), James W. Huston (Author)


EMPOWER YOURSELF! Whether you’re a newly diagnosed myeloma patient, a survivor, or a friend or relative of either, this book offers help. The only text to provide the doctor’s and patient’s views, 100 Questions & Answers About Myeloma, Third Edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a hematologist-oncologist specializing in myeloma treatment, and featuring “insider” advice from an actual patient, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease.

Multiple Myeloma: Learn What Is Cause, Risk Factors, Symptoms, Diagnosis, Treatment and Health Care (Illustrated)

Multiple Myeloma: Learn What Is Cause, Risk Factors, Symptoms, Diagnosis, Treatment and Health Care (Illustrated)


Multiple Myeloma - Enhanced Edition: Learn What Is Cause, Risk Factors, Symptoms, Diagnosis, Treatment and Health Care (Annotated and Illustrated) provides you overall information about brain tumor. This book was written by Medical Professionals from National Cancer Institute with scientific details. You will learn the cause, risk factors, symptoms, treatments, etc that will helpful for both readers who are interesred in health and whoever have a member in family suffer from cancer. Moreover, this edition of the book includes;

- Eating Hints: Before, During, and After Cancer Treatment

- Follow-up Care After Cancer Treatment

- How To Find a Doctor or Treatment Facility If You Have Cancer

- Facing Forward: Life After Cancer Treatment

-...

Multiple Myeloma: Diagnosis and Treatment

Multiple Myeloma: Diagnosis and Treatment
by Morie A. Gertz (Editor), S. Vincent Rajkumar (Editor)


This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care.Our understanding of this group of disorders is developing at an unprecedented rate, and...

© 2017 BrightSurf.com